Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An eight-week, double-blind, placebo-controlled, multicenter study with paroxetine (10 mg qd) as positive control, evaluating the efficacy, safety, tolerability of two fixed doses of SR58611A [amibegron] (175 mg q12/ 350 mg q12) in outpatients with major depressive disorder (MDD)

Next Previous
Trial Profile

An eight-week, double-blind, placebo-controlled, multicenter study with paroxetine (10 mg qd) as positive control, evaluating the efficacy, safety, tolerability of two fixed doses of SR58611A [amibegron] (175 mg q12/ 350 mg q12) in outpatients with major depressive disorder (MDD)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jul 2009

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amibegron (Primary) ; Paroxetine
  • Indications Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Acronyms SIRIUS
  • Sponsors Sanofi

Most Recent Events

  • 07 Jul 2009 Actual patient number changed from 667 to 680 as reported by ClinicalTrials.gov.
  • 14 Sep 2008 Actual end date (Nov 2007) added as reported by ClinicalTrials.gov.
  • 14 Sep 2008 Actual patient number (667) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top